Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Gloria Bio Approved to Launch anti-PD-1 for Metastatic Cervical Cancer

publication date: Sep 6, 2023

Guangzhou Gloria Biosciences was approved to launch its anti-PD-1 mAb, zimberelimab injection, as a second line monotherapy for recurrent or metastatic cervical cancer patients with positive PD-L1 expression. Patients must have progressed on or after platinum-based chemotherapy. Gloria pointed out that zimberelimab is the only immune checkpoint inhibitor antibody approved in China for cervical cancer and the third one globally. Gloria developed the PD-1 in partnership with WuXi Biologics, and the two companies sold ex-China rights to California’s Arcus Biosciences in a $818 million agreement. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital